Fresh off an initial public offering earlier this year, cancer immunotherapy pioneer Adaptimmune Therapeutics is injecting $25 million into the local economy through renowned Malvern developer Liberty Property Trust.

Liberty will bring the company’s vision for a 46,000-square-foot facility employing 110 new employees to reality at the growing Navy Yard Corporate Center in Philly, which already boasts pharmaceutical players GlaxoSmithKline, Iroko Pharmaceuticals and WuXi AppTec according to a recent Philadelphia Business Journal report.

“This new facility will allow Adaptimmune to more than triple the number of its employees in Pennsylvania with well-paying positions that will contribute to the overall economic growth in the city and region,” CEO James Noble said in the article. “We see our commitment to the Navy Yard as a vote of confidence in Pennsylvania as a powerhouse for scientific and medical achievement.”

Read more about Adaptimmune and its proposed new Liberty Property Trust-led development in the Philadelphia Business Journal here, and check out what else Liberty has in the works at the Navy Yard and elsewhere through previous VISTA Today coverage here.